Article: FDA approves doxycycline tablets, 150 mg.(PIPELINE PREVIEWS)(Mylan Laboratories Inc.)(Brief article)

Mylan Laboratories Inc recently announced that it has received FDA approval for doxycycline tablets, 150 mg. This medication will be the equivalent generic version of Par Pharmaceutical's doxycycline tablets, 150 mg which are currently marketed by Doak Dermatologics under the brand name Adoxa[R] Tablets. Mylan already has approval and has been marketing doxycycline tablets in 50, 75, and 10 mg strengths.

Marissa Heller MD

Department of Dermatology, Boston University School of Medicine

Pipeline Previews brings you information on the newest ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!